76%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
76%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
76%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
76%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Coloplast A-S (Class B)
Closed
603.4 0.4
Overview
Share price change
24h
Min
577
Max
611.4
Income | -132M 912M |
|---|---|
Sales | -96M 6.9B |
P/E Sector Avg | 29.385 39.564 |
EPS | 5.45 |
Dividend yield | 3.66 |
Profit margin | 13.16 |
Employees | 16,741 |
EBITDA | 2.2B |
Recommendations | Neutral |
|---|---|
12 Months Forecast | +11.86% upside |
Dividend yield Sector Avg | 3.66% 2.40% |
|---|---|
Next Earnings | 19 Aug 2025 |
Market Cap | -24B 134B |
|---|---|
Previous open | 603 |
Previous close | 603.4 |
Coloplast A-S (Class B) Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Coloplast A-S (Class B) Forecast
Price Target
By TipRanks
11.86% upside
12 Months Forecast
Average 901.38 DKK 11.86%
High 1,056 DKK
Low 720 DKK
Based on 8 Wall Street analysts offering 12 month price targets forColoplast A-S (Class B) - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Coloplast A-S (Class B)
Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; and Peristeen Plus, a transanal irrigation system. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand; and skin care products that include cleansers, moisturizers, skin protectants, antifungal products, and hand cleansers, as well as InterDry, a skin fold management solution. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Additionally, its voice and respiratory care solutions include laryngectomy care products comprising Provox, a voice prosthesis for speaking, HMEs, adhesives, laryngectomy tubes for breathing, devices for speaking hands-free, and accessories, as well as tracheostomy care products under Tracoe brand. Coloplast A/S was founded in 1954 and is headquartered in Humlebæk, Denmark.
